Announcements Trials
Browse Landscape

Phase

Phase 1 13Phase 2 5Phase 1/2 2Phase NA 1Phase 3 1

Status

Terminated 5Completed 5Unknown 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Urologic Neoplasms 1Urogenital Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Completed × motexafin gadolinium × Clear all
NCT00022256 2013-06-18

Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00129844 2008-08-20

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Completed
108 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00086034 2007-05-15

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Pharmacyclics LLC.

Phase 2 Completed
35 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT00134186 2007-03-05

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Pharmacyclics LLC.

Phase 2 Completed
43 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

NCT00096837 2006-06-08

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Pharmacyclics LLC.

Phase 2 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡